A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Официальное название

A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

Обзор

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1), and the safety, tolerability, and PD of multiple doses of ARO-ALK7 in adult participants with obesity with and without T2DM, either as monotherapy or in combination with tirzepatide (Part 2).

Вмешательства

• Препарат ARO-ALK7
  Subcutaneous (SC) injection
• Препарат Placebo
  calculated volume to match active treatment by SC injection

Первичные конечные точки

• Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [Срок оценки: Up to Day 253 End of Study (EOS)]

Вторичные конечные точки (11)

• Pharmacokinetics (PK) of ARO-ALK7 (Part 1 Only): Maximum Observed Plasma Concentration (Cmax) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Time to Maximum Observed Plasma Concentration (Tmax) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Quantifiable Plasma Concentration (AUC0-t) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUC0-∞) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Terminal Elimination Half-life (t1/2) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Apparent Systemic Clearance (CL/F) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Apparent Terminal-phase Volume of Distribution (Vz/F) [Срок оценки: Through 48 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Recovery of Unchanged Drug in Urine from Time 0 to 24 Hours after Dosing (Amount excreted: Ae) [Срок оценки: Through 24 hours post-dose]
• PK of ARO-ALK7 (Part 1 Only): Fraction or Percentage of Administered Drug Excreted in Urine from Time 0 to 24 Hours after Dosing (Fe) [Срок оценки: Through 24 hours post-dose]
• PK of ARO-ALK7: Renal Clearance (CLr) [Срок оценки: Through 24 hours post-dose]

Критерии участия

Критерии включения

• Obesity, defined as body mass index (BMI) between 30-50 kilograms (kg)/square meter (m\^2), inclusive, with weight at Screening not to exceed 159 kg (350 pounds \[lbs\])
• At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification
• No abnormal finding of clinical relevance at Screening that could adversely impact participant safety during the study or adversely impact study results
• Female participants of childbearing potential must agree to use highly effective contraception and male participants with female partners of childbearing potential must agree to use a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later. Participants must not donate sperm or eggs during the study for at least 90 days following the end of the study or last dose of study drug, whichever is later

Критерии исключения

• Self-reported (or documented) weight gain or loss >5% within 3 months prior to Screening
• Use of glucagon-like peptide-1 receptor agonist (GLP-1RAs) (liraglutide, semaglutide, etc.) for any indication within 6 months prior to Screening
• Use of non-GLP-1R medications for weight loss within 3 months prior to Screening, including but not limited to naltrexone/bupropion, orlistat, phentermine/topiramate, and other prescription or over-the-counter medication or supplement taken for weight loss purposes
• Obesity attributable primarily in the Investigator's opinion to medication use, monogenic or endocrinologic disorders (other than polycystic ovary syndrome)
• History of prior surgical or device-based therapy for obesity (including endoscopic bariatric procedures)
• Use of medications or therapies strongly associated with weight gain, alterations in body composition, or increase in muscle mass, within 3 months prior to Screening
• Type 1 diabetes mellitus

Note: Additional inclusion/exclusion criteria may apply per protocol.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Новая Зеландия · 6 центров

• Research Site 5 — Grafton
• Research Site 6 — Papatoetoe
• Research Site 3 — Takapuna
• Research Site 1 — Auckland
• Research Site 2 — Christchurch
• Research Site 4 — Rotorua

Австралия · 2 центра

• Research Site 8 — Morayfield
• Research Site 7 — Nedlands

Идентификаторы

NCT: NCT06937203 · AROALK7-1001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗